Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
Karyopharm Therapeutics Inc. logo

NASDAQ · KPTI

Karyopharm Therapeutics Inc.

Healthcare · Biotechnology

$1.54

Down-$0.06 (-3.75%)

Updated Sep 16, 2026, 8:12 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
59.5M
P/E ratio
-0.48
Dividend yield
0.00%
52-week range
$1.24 – $10.86
Volume
1.33M
Avg. volume
181.65K

Price performance

KPTI price history

1M range · 20 trading sessions · Daily adjusted prices

KPTI closed at $1.54 after 20 trading sessions, down 20.21% for the selected period.

Last close
$1.54
Period change
-20.21%
Period low
$1.54
Period high
$2.06
Daily close
View OHLC price history
KPTI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.59$1.70$1.525$1.541.33M
Sep 14, 2026$1.55$1.62$1.55$1.60991.81K
Sep 11, 2026$1.50$1.61$1.24$1.616.74M
Sep 10, 2026$1.68$1.68$1.595$1.62800.95K
Sep 9, 2026$1.72$1.75$1.65$1.69772.57K
Sep 8, 2026$1.77$1.79$1.70$1.721.01M
Sep 4, 2026$1.77$1.84$1.755$1.79577.79K
Sep 3, 2026$1.79$1.8062$1.72$1.77819.68K
Sep 2, 2026$1.90$1.94$1.725$1.791.3M
Sep 1, 2026$2.02$2.065$1.84$1.851.6M
Aug 31, 2026$1.91$2.14$1.7907$2.062.03M
Aug 28, 2026$1.98$1.99$1.86$1.87827.35K
Aug 27, 2026$1.99$2.06$1.9301$1.941.11M
Aug 26, 2026$1.92$1.99$1.86$1.96753.81K
Aug 25, 2026$1.87$1.95$1.87$1.921.06M
Aug 24, 2026$1.95$1.96$1.83$1.86845.77K
Aug 21, 2026$1.85$1.97$1.822$1.96876.79K
Aug 20, 2026$2.00$2.00$1.82$1.82865.65K
Aug 19, 2026$1.93$2.0153$1.93$2.00792.13K
Aug 18, 2026$1.88$1.96$1.82$1.931.15M

Latest KPTI news

The latest Smart Investors Daily articles mentioning KPTI.

Stock researchCompany · Overview

KPTI research

Overview

Company profile and research snapshot.

Company profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.25
Implied upside
—
Analysts
—
KPTI recent ratings
DateFirmRatingTarget
Jul 31, 2026Piper SandlerOverweight—
Jul 31, 2026HC Wainwright & Co.Neutral—
May 6, 2026HC Wainwright & Co.Buy—
Apr 27, 2026Piper SandlerOverweight—
Mar 30, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...

Yahoo · Sep 1, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of August 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nas

Yahoo · Aug 31, 2026

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis. Karyopharm requested Priority Review of the application, which, if granted, could result in a six-month review process.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By